Silvia Vandeva

Silvia Vandeva

Auto-generated profile, based on publicly available information

Silvia Vandeva

Department of Endocrinology, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Endocrine
Verified
Journal Article
Closed access
PDF file
AEAtanaska Elenkova
Atanaska Elenkova
IАIliana Аtanasova
Iliana Аtanasova
GKGeorgi Kirilov
Georgi Kirilov
ЕNЕmil Natchev
Еmil Natchev
RIRalitza Ivanova
Ralitza Ivanova
SZSabina Zacharieva
Sabina Zacharieva

1 May 2020
Verified
Journal Article
Open access
ENEmil Natchev
Emil Natchev
SVSilvia Vandeva
Silvia Vandeva
RKRoussanka Kovatcheva
Roussanka Kovatcheva
GKGeorgi Kirilov
Georgi Kirilov
KKKrasimir Kalinov
Krasimir Kalinov
SZSabina Zacharieva
Sabina Zacharieva
Objective: Acromegaly is characterized by high neoplastic morbidity as a side effect of growth hormone (GH) hypersecretion. Increased incidence of goiter, thyroid carcinoma, and thyroid dysfunction is also reported. The aim of the present study was to find the prevalence of thyroid dysfunction and goiter in patients with acromegaly and determine its relationship to disease activity, disease duration, and the presence of secondary hypothyroidism. Subjects and methods: In a cross-sectional study of the period 2008-2012 were included 146 patients with acromegaly (56 men, 90 women) of mean age 50.3 +/- 12.4 years. Acromegaly disease activity and thyroid function were evaluated in all patients. Thyroid ultrasonography was performed to calculate thyroid volume and detect the presence of nodular goiter. Results: Ninety-one patients were determined to have an active disease, and 55, a controlled disease. The mean thyroid volume in patients without previous thyroid surgery was 37.6 +/- 38.8 mL. According to disease activity, thyroid volume was significantly higher in patients with active disease (38.5 +/- 45.4 mL vs. 27.2 +/- 18.4 mL, p = 0.036). A weak positive correlation was found between thyroid volume and insulin-like growth factor 1 (IGF-1) in the whole group and in females (R = 0.218; p = 0.013, and R = 0.238; p = 0.037, respectively). There was no significant correlation of thyroid volume with disease duration and GH level in the whole group and in both sexes. The patients with secondary hypothyroidism had twofold smaller thyroid volume, relative to the rest of the group. The prevalence of thyroid dysfunction was 39%, with a female to male percentage ratio of 1.73. Goiter was diagnosed in 87% of patients, including diffuse goiter (17.1%) and nodular (69.9%), with no significant difference between patients with active and controlled disease or the presence of secondary hypothyroidism. Conclusions: Thyroid volume in patients with acromegaly depends on disease activity and the presence of secondary hypothyroidism as a complication. The increased prevalence of nodular goiter determines the need of regular ultrasound thyroid evaluation in the follow-up of patients with acromegaly.

24 September 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
APAleksina Parvanova
Aleksina Parvanova
Petya MilushewaPetya Milushewa
Petya Milushewa
KTKonstantin Tachkov
Konstantin Tachkov
SVSilvia Vandeva
Silvia Vandeva
AEAtanaska Elenkova
Atanaska Elenkova
Introduction : The development of medicine and the introduction of new therapeutic options are leading to increasing scientific attention to rare diseases (RDs) affecting older adults. This requires the application of a systematic approach to drug therapy, with a focus on the identification and management of drug-related problems (DRPs). Objectives : To systematically review the evidence on DRPs in older adults with rare diseases and to evaluate DRPs in a real-world cohort of older patients with acromegaly. Methods : A three-step approach was applied: (1) a systematic review of the literature on DRPs in geriatric patients with RDs; (2) a retrospective study of patients with acromegaly hospitalized at the Expert Center of Rare Endocrine Diseases, University Hospital for Active Treatment in Endocrinology (USHATE) “Acad. Ivan Penchev,” Sofia, Bulgaria, in 2021, with application of the STOPP/START criteria for the assessment of DRPs; and (3) an exploratory analysis of the odds of experiencing a DRP according to the presence of polypharmacy and multimorbidity. Results : A total of six studies met the inclusion criteria in the systematic review. The most common DRPs were associated with therapeutic failure and adverse drug reactions (ADRs), which were inherently serious because they led to hospitalization or death. Based on the retrospective study, a total of 16 DRPs were identified among 42 geriatric patients with acromegaly. Ten potentially inappropriate medications and four cases of prescribing omissions were identified, and a review of the Summary of Product Characteristics revealed two additional DRPs. The variables polypharmacy (OR = 1.3043, p = 0.7701) and multimorbidity (OR = 3.9804, p = 0.3720) were not statistically significant factors for the development of DRPs in the study group. Conclusion : The study identified clinically relevant DRPs and demonstrated the potential value of tools such as the STOPP/START criteria in evaluating therapy in geriatric patients. The results highlight that, despite the severity of DRPs, some of them can be identified and prevented through comprehensive pharmacotherapeutic analysis. This emphasizes the need for more in-depth research on risk factors and long-term follow-up by a clinical pharmacist to optimize pharmacotherapy.

1 June 2011
Verified
Book Chapter
Closed access
SVSilvia Vandeva
Silvia Vandeva
MYMaria Yaneva
Maria Yaneva
RARenata S Auriemma
Renata S Auriemma
Rosario PivonelloRosario Pivonello
Rosario Pivonello
ENEmil Nachev
Emil Nachev
Annamaria ColaoAnnamaria Colao
Annamaria Colao
Article published by the Endocrine Society Article published by the Endocrine Society